Latest Earnings Results: Q2 '26
Estimated EPS
-$0.19
Reported EPS
-$0.15
Surprise
+22.79%
Estimated Rev
$38.56M
Reported Rev
$45.69M
Surprise
+18.49%
• Reported GAAP EPS of -$0.15 up 16.67% YoY • Reported revenue of $45.69M up 118.37% YoY • Autolus Therapeutics increased its full year 2026 guidance for AUCATZYL net product revenue to $140 million to $150 million, up from the previous range of $120 million to $135 million.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | -$0.16 | -- | -- | N/A |
Q2 '26 | -$0.19 | -$0.15 | 22.79% | BEAT |
Q1 '26 | -$0.25 | -$0.27 | -6.73% | MISSED |
Q4 '25 | -$0.27 | -$0.34 | -25.55% | MISSED |
Q3 '25 | -$0.21 | -$0.30 | -39.94% | MISSED |